NKGen Biotech, Inc. Common Stock
NKGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -81.9% | – |
| Cost of Goods Sold | $0 | $1 | $0 | $0 |
| Gross Profit | $0 | -$1 | $0 | $0 |
| % Margin | – | – | 76.6% | 93% |
| R&D Expenses | $11 | $14 | $17 | $15 |
| G&A Expenses | $16 | $0 | $8 | $8 |
| SG&A Expenses | $16 | $14 | $8 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | -$0 |
| Operating Expenses | $27 | $29 | $24 | $22 |
| Operating Income | -$27 | -$30 | -$24 | -$22 |
| % Margin | – | – | -31,618.2% | -5,131.7% |
| Other Income/Exp. Net | -$17 | -$53 | -$2 | -$1 |
| Pre-Tax Income | -$44 | -$83 | -$27 | -$23 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$44 | -$83 | -$27 | -$23 |
| % Margin | – | – | -34,745.5% | -5,461.3% |
| EPS | -1.54 | -5.38 | -1.25 | -1.08 |
| % Growth | 71.4% | -330.4% | -15.7% | – |
| EPS Diluted | -1.54 | -5.38 | -1.25 | -1.08 |
| Weighted Avg Shares Out | 29 | 15 | 21 | 21 |
| Weighted Avg Shares Out Dil | 29 | 15 | 21 | 21 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $3 | $1 | $2 | $1 |
| Depreciation & Amortization | $0 | $1 | $1 | $1 |
| EBITDA | -$27 | -$81 | -$23 | -$21 |
| % Margin | – | – | -30,170.1% | -4,859.4% |